| Idaho Complete Foot Care | |
|
880 Redman St, Chubbuck, ID 83202-2655 | |
| (208) 681-2353 | |
| Not Available |
| Full Name | Idaho Complete Foot Care |
|---|---|
| Type | Facility |
| Speciality | Podiatrist |
| Location | 880 Redman St, Chubbuck, Idaho |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740824762 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Idaho Complete Foot Care 880 Redman St, Chubbuck, ID 83202-2655 Ph: (208) 681-2353 | Idaho Complete Foot Care 880 Redman St, Chubbuck, ID 83202-2655 Ph: (208) 681-2353 |
News Archive
Pain Therapeutics, Inc., a biopharmaceutical company, today reported second quarter financial results. Net loss for the quarter ended June 30, 2010 was $0.8 million, or $0.02 per share, compared to net loss of $34,000, or $0.00 per share, for the second quarter of 2009. Pain Therapeutics had cash, cash equivalents and marketable securities of $176.2 million, or about $4.14 cash per share, and no debt as of June 30, 2010.
With implementation of conservative treatment methods like physiotherapy and individually tailored, adjusted exercises, quality of osteoarthritis care can improve and patients can delay the need for an artificial hip or knee joint.
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the Phase 1 study of UX001 for hereditary inclusion body myopathy (HIBM) has been completed.
A study, available on the pre-print server medRxiv, has determined the underlying molecular mechanisms of how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially the G614 strain, leads to olfactory dysfunction causing anosmia.
› Verified 7 days ago